Work

CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.tps9103

Authors: F. Stephen Hodi, Asim Amin, Yvonne M. Saenger, Gregory K. Pennock, Troy H. Guthrie, April K. Salama, Lawrence E. Flaherty, Henry B. Koon, David H. Lawson, Montaser F. Shaheen, Agnes Balogh, Cyril Konto, Steven O'Day

Institutions: Dana-Farber Cancer Institute, Levine Cancer Institute, Icahn School of Medicine at Mount Sinai, Baptist Cancer Center, Duke University, Duke Cancer Institute, Wayne State University, University Hospitals of Cleveland, Emory University, UNM Comprehensive Cancer Center, Bristol-Myers Squibb (Belgium), Bristol-Myers Squibb (United States), Beverly Hills Cancer Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597635018

Cites:

Cited by: 4

Related to: 10